List of Xeljanz Xr drug patents

Xeljanz Xr is owned by Pfizer.

Xeljanz Xr contains Tofacitinib Citrate.

Xeljanz Xr has a total of 5 drug patents out of which 0 drug patents have expired.

Xeljanz Xr was authorised for market use on 23 February, 2016.

Xeljanz Xr is available in tablet, extended release;oral dosage forms.

Xeljanz Xr can be used as a method of treating ankylosing spondylitis by administering the formulation of tofacitinib of claims 1, 8, 15-20, 27-31, 34-43, 45, 47, 49, 50, 54, 59, 63, 68-71, 73, 77, 82-84, and 87-98; a method of treating psoriatic arthritis by administering the formulation of tofacitinib of claims 1, 8, 15-20, 27-31, 34-44, 46, 48, 50, 53, 59, 62, 68-71, 73, 76, 82-84, and 87-98; a method of treating rheumatoid arthritis by administering the formulation of tofacitinib of claims 1, 2, 8, 9, 15-21, 27-31, 34-43, 50, 51, 59, 60, 68-71, 73, 74, 82-84 and 87-98; a method of treating ulcerative colitis, by administering the formulation of tofacitinib of claims 1, 3, 8, 10, 15-20, 22, 27-31, 34-43, 50, 52, 59, 61, 68-71, 73, 75, 82-84 and 87-98.

The generics of Xeljanz Xr are possible to be released after 14 March, 2034.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6965027 PFIZER Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate
Mar, 2023

(a month from now)

USRE41783 PFIZER Pyrrolo[2,3-D]pyrimidine compounds
Dec, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11253523 PFIZER Tofacitinib oral sustained release dosage forms
Mar, 2034

(11 years from now)

US9937181 PFIZER Tofacitinib oral sustained release dosage forms
Mar, 2034

(11 years from now)

US10639309 PFIZER Tofacitinib oral sustained release dosage forms
Mar, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Dec 14, 2024

Drugs and Companies using TOFACITINIB CITRATE ingredient

Market Authorisation Date: 23 February, 2016

Treatment: A method of treating ankylosing spondylitis by administering the formulation of tofacitinib of claims 1, 8, 15-20, 27-31, 34-43, 45, 47, 49, 50, 54, 59, 63, 68-71, 73, 77, 82-84, and 87-98; A method of treating psoriatic arthritis by administering the formulation of tofacitinib of claims 1, 8, 15-20, 27-31, 34-44, 46, 48, 50, 53, 59, 62, 68-71, 73, 76, 82-84, and 87-98; A method of treating rheumatoid arthritis by administering the formulation of tofacitinib of claims 1, 2, 8, 9, 15-21, 27-31, 34-43, 50, 51, 59, 60, 68-71, 73, 74, 82-84 and 87-98; A method of treating ulcerative colitis, by administering the formulation of tofacitinib of claims 1, 3, 8, 10, 15-20, 22, 27-31, 34-43, 50, 52, 59, 61, 68-71, 73, 75, 82-84 and 87-98

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of XELJANZ XR before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in